Alzheimer's to triple by 2050 as baby boomers age

Key points
- The number of U.S. residents aged 65 and older living with Alzheimer's disease is expected to nearly triple to 13.8 million by 2050 as aging baby boomers swell the ranks of those living with the brain-wasting disease, U.S. researchers said on Wednesday.
- The researchers estimate that the total number of U.S. residents with Alzheimer's in 2050 could reach 13.8 million, up from 4.7 million in 2010.
- The new estimates, published in the journal Neurology, confirm prior estimates and make clear the need for new and better treatments for Alzheimer's, the leading cause of dementia that now affects some 5 million Americans and 38 million people worldwide.
- The latest U.S. estimates paint a grim picture as more and more of the nation's baby boom generation pass the age of 65, putting them at higher risk for Alzheimer's, an age-related disorder that slowly robs its victims of the ability to think and care for themselves.
The number of U.S. residents aged 65 and older living with Alzheimer's disease is expected to nearly triple to 13.8 million by 2050 as aging baby boomers swell the ranks of those living with the brain-wasting disease, U.S. researchers said on Wednesday.
The new estimates, published in the journal Neurology, confirm prior estimates and make clear the need for new and better treatments for Alzheimer's, the leading cause of dementia that now affects some 5 million Americans and 38 million people worldwide.
The latest U.S. estimates paint a grim picture as more and more of the nation's baby boom generation pass the age of 65, putting them at higher risk for Alzheimer's, an age-related disorder that slowly robs its victims of the ability to think and care for themselves.
"Our study draws attention to an urgent need for more research, treatments and preventive strategies to reduce this epidemic," said study co-author Jennifer Weuve, an assistant professor of medicine at Rush University Medical Center in Chicago.
The National Institute on Aging and others say Alzheimer's represents a looming health epidemic as the population ages. Current drugs treat symptoms, but no treatments can stop the progression of Alzheimer's despite millions of dollars being spent on research.
The most recent attempts have failed or met with only faint success. Eli Lilly and Co's solanezumab failed last summer to meet the primary goals of two studies in patients with mild to moderate Alzheimer's, but showed a slight benefit when the studies were pooled to look at the effect on those with the mildest form of the disease.
Lilly plans to start a new trial in patients with mild Alzheimer's this year.
For the latest estimates, the researchers used data on thousands of older volunteers in a community study of Alzheimer's in Chicago, combined with data on U.S. death rates, education and current and future population estimates from the U.S. census.
RISING VICTIMS WITHOUT A CURE
The researchers estimate that the total number of U.S. residents with Alzheimer's in 2050 could reach 13.8 million, up from 4.7 million in 2010. That includes about 7 million people who would be age 85 or older in 2050.
"These projections are based on assumptions that we don't have a cure at this point, and people may be living longer going forward," said Dallas Anderson of the National Institute on Aging, one of the National Institutes of Health, which funded the study along with the Alzheimer's Association.
"The baby boom bulge is finally reaching retirement age and moving into the age window of highest risk," he said.
Anderson said the study is an update of a prior report done a decade ago, and while the numbers are similar, the new assumptions are the most up to date.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Mental Health →
NewsAlzheimer’s research, education needs funding
This year in America we will spend $2.03 billion on Alzheimer’s disease and two-thirds of that will be paid by Medicare and Medicaid. The costs will skyrocket to an estimated $1.2 trillion by 2050. Based on a National…
8 July 2013
NewsUCSB research points to a potential therapeutic approach to Alzheimer's disease
Building on research published eight years ago in the journal Chemistry and Biology, Kenneth S. Kosik, Harriman Professor in Neuroscience and co-director of the Neuroscience Research Institute (NRI) at UC Santa Barbara,…
27 June 2013
NewsChina's Alzheimer's time bomb revealed
In 2010, China had more people living with Alzheimer's disease than any other country in the world – and twice as many cases of Alzheimer's and other kinds of dementia as the World Health Organization thought. Cases of…





